What is RKVTF?
, a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.29M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.